Recent Press Releases
2019
2015
2014
5/14/2014
Plexxikon Announces PLX3397 Data Presentations at ASCO 2014 Annual Meeting
2013
5/31/2013
Plexxikon Announces Program Update and Management Changes
2012
11/8/2012
Plexxikon Announces Three-Year Survival in Zelboraf-Treated Metastatic Melanoma Patients
2011
12/12/2011
Plexxikon Advances Novel Targeted Treatment of PLX3397 in Blood Cancer
11/13/2011
Plexxikon Novel Agents Aim To Address Cancer Treatment in New Ways
6/5/2011
Plexxikon Reports Positive Data from Phase 3 and Phase 2 Trials of Vemurafenib (PLX4032)
6/2/2011
Plexxikon Announces Combination Trials for Vemurafenib in Melanoma
5/10/2011
New Drug Applications Submitted for Vemurafenib Market Approval in Melanoma
4/4/2011
Daiichi Sankyo Completes Plexxikon Acquisition
3/8/2011
Plexxikon Initiates Phase 2 Clinical Trial in Hodgkin Lymphoma with PLX3397
2/28/2011
Daiichi Sankyo To Acquire Plexxikon
1/27/2011
Plexxikon Initiates Phase 1 Clinical Trial for Oral Rheumatoid Arthritis Agent PLX5622
1/18/2011
Plexxikon Reports Overall Survival Benefit for Melanoma Patients in PLX4032 Phase 3 Trial
1/6/2011
Plexxikon Signs Agreement with Genentech to Co-Promote PLX4032 in the US
2010-2009
Archived Press Releases (2010-2009)